Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis

Jamie R. Felzer; Delvise T. Fogwe; Shaher Samrah; Clement J. Michet; Ulrich Specks; Misbah Baqir; Aahd F. Kubbara

doi:10.1002/rcr2.894

Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis

Jamie R. Felzer, Delvise T. Fogwe, Shaher Samrah, Clement J. Michet, Ulrich Specks, Misbah Baqir, Aahd F. Kubbara

Research output: Contribution to journal › Article › peer-review

Abstract

Inflammatory processes, such as an infection or drug reaction, can cause antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). Although quite rare, AAV may occur with SARS-coronavirus disease 2019 (COVID-19) antigenic exposure, either from infection or immunization. We present two cases of AAV: one that developed after COVID-19 infection presenting as diffuse alveolar haemorrhage and another that developed shortly after vaccination, presenting as granulomatous pulmonary nodules. Both patients improved with supportive care and immunosuppressive therapies. This adverse event appears to be a very rare complication of COVID-19 infection or vaccination. Early diagnosis of AAV is important because immunosuppressive therapy may improve patient outcomes.

Original language	English (US)
Article number	e0894
Journal	Respirology Case Reports
Volume	10
Issue number	1
DOIs	https://doi.org/10.1002/rcr2.894
State	Published - Jan 2022

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1002/rcr2.894

Cite this

@article{5650ac8e64ea456ea0279bc8a63c9dd3,

title = "Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis",

abstract = "Inflammatory processes, such as an infection or drug reaction, can cause antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). Although quite rare, AAV may occur with SARS-coronavirus disease 2019 (COVID-19) antigenic exposure, either from infection or immunization. We present two cases of AAV: one that developed after COVID-19 infection presenting as diffuse alveolar haemorrhage and another that developed shortly after vaccination, presenting as granulomatous pulmonary nodules. Both patients improved with supportive care and immunosuppressive therapies. This adverse event appears to be a very rare complication of COVID-19 infection or vaccination. Early diagnosis of AAV is important because immunosuppressive therapy may improve patient outcomes.",

author = "Felzer, {Jamie R.} and Fogwe, {Delvise T.} and Shaher Samrah and Michet, {Clement J.} and Ulrich Specks and Misbah Baqir and Kubbara, {Aahd F.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.",

year = "2022",

month = jan,

doi = "10.1002/rcr2.894",

language = "English (US)",

volume = "10",

journal = "Respirology Case Reports",

issn = "2051-3380",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis

AU - Felzer, Jamie R.

AU - Fogwe, Delvise T.

AU - Samrah, Shaher

AU - Michet, Clement J.

AU - Specks, Ulrich

AU - Baqir, Misbah

AU - Kubbara, Aahd F.

PY - 2022/1

Y1 - 2022/1

N2 - Inflammatory processes, such as an infection or drug reaction, can cause antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). Although quite rare, AAV may occur with SARS-coronavirus disease 2019 (COVID-19) antigenic exposure, either from infection or immunization. We present two cases of AAV: one that developed after COVID-19 infection presenting as diffuse alveolar haemorrhage and another that developed shortly after vaccination, presenting as granulomatous pulmonary nodules. Both patients improved with supportive care and immunosuppressive therapies. This adverse event appears to be a very rare complication of COVID-19 infection or vaccination. Early diagnosis of AAV is important because immunosuppressive therapy may improve patient outcomes.

AB - Inflammatory processes, such as an infection or drug reaction, can cause antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). Although quite rare, AAV may occur with SARS-coronavirus disease 2019 (COVID-19) antigenic exposure, either from infection or immunization. We present two cases of AAV: one that developed after COVID-19 infection presenting as diffuse alveolar haemorrhage and another that developed shortly after vaccination, presenting as granulomatous pulmonary nodules. Both patients improved with supportive care and immunosuppressive therapies. This adverse event appears to be a very rare complication of COVID-19 infection or vaccination. Early diagnosis of AAV is important because immunosuppressive therapy may improve patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85121802603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121802603&partnerID=8YFLogxK

U2 - 10.1002/rcr2.894

DO - 10.1002/rcr2.894

M3 - Article

AN - SCOPUS:85121802603

SN - 2051-3380

VL - 10

JO - Respirology Case Reports

JF - Respirology Case Reports

IS - 1

M1 - e0894

ER -

Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this